2002 Annual Reports: Money and Pharmaceuticals
Abstract
Managed Care 2002 Annual Reports: Money and Pharmaceuticals Even though it is already Lillyâs best-selling product ever, Zyprexa still has impressive opportunities for new growth. For example, we believe it can become the medicine of choice in treating all phases of bipolar disorder, an illness that afflicts twice as many people as schizophrenia. Sidney Taurel Chairman of the Board, President, and Chief Executive Officer Eli Lilly and Company Annual Report 2002 Global sales of antidepressants are $16.7 billion. Zoloft is the most prescribed selective serotonin reuptake inhibitor in the U.S. and a leading medicine worldwide for treating depression, as well as panic disorder, obsessive/compulsive disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and acute and long-term treatment of social anxiety disorder (for which it was approved in February 2003). Sales of Zoloft in 2002 grew 16% to $2.7 billion. Regulatory review of Zoloft in the U.S. is under way for use in pediatric depression. Pfizer Annual Report 2002 Effexor XR was among the fastest growing antidepressants in the United States during 2002. We expect the Effexor family to continue to grow rapidly in 2003, as it remains on track to exceed sales of $3 billion in 2004. Wyeth Annual